SANTA CLARA, Calif.--DiaDexus, a joint venture between Smith Kline Beecham and Incyte pharmaceuticals here, announced the formation of its scientific advisory board. The company is dedicated to the discovery and commercialization of novel molecular diagnostic products focused on disease detection. Major research areas include oncology, microbiology, and pharmacogenomics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.